UBS Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $282M | Buy |
630,618
+74,636
| +13% | +$34.8M | 0.04% | 455 |
|
|
2025
Q4 | $252M | Sell |
555,982
-217,066
| -28% | -$93.6M | 0.04% | 464 |
|
|
2025
Q3 | $303M | Buy |
773,048
+73,046
| +10% | +$30.5M | 0.05% | 389 |
|
|
2025
Q2 | $312M | Sell |
700,002
-37,416
| -5% | -$17.2M | 0.05% | 354 |
|
|
2025
Q1 | $358M | Sell |
737,418
-125,618
| -15% | -$58.5M | 0.07% | 299 |
|
|
2024
Q4 | $348M | Buy |
863,036
+88,821
| +11% | +$41.2M | 0.06% | 289 |
|
|
2024
Q3 | $360M | Buy |
774,215
+179,835
| +30% | +$86.4M | 0.08% | 241 |
|
|
2024
Q2 | $279M | Buy |
594,380
+22,200
| +4% | +$9.64M | 0.07% | 266 |
|
|
2024
Q1 | $239M | Buy |
572,180
+148,474
| +35% | +$62.8M | 0.06% | 312 |
|
|
2023
Q4 | $172M | Buy |
423,706
+71,008
| +20% | +$26.2M | 0.05% | 358 |
|
|
2023
Q3 | $123M | Sell |
352,698
-131,183
| -27% | -$45.9M | 0.04% | 424 |
|
|
2023
Q2 | $170M | Sell |
483,881
-58,264
| -11% | -$19.6M | 0.06% | 326 |
|
|
2023
Q1 | $171M | Sell |
542,145
-63,417
| -10% | -$19M | 0.06% | 301 |
|
|
2022
Q4 | $175M | Buy |
605,562
+322,784
| +114% | +$98.4M | 0.07% | 311 |
|
|
2022
Q3 | $81.9M | Sell |
282,778
-25,916
| -8% | -$7.46M | 0.04% | 496 |
|
|
2022
Q2 | $87M | Sell |
308,694
-102,651
| -25% | -$27.5M | 0.04% | 501 |
|
|
2022
Q1 | $107M | Buy |
411,345
+54,874
| +15% | +$13M | 0.04% | 502 |
|
|
2021
Q4 | $78.3M | Sell |
356,471
-146,377
| -29% | -$28.5M | 0.02% | 710 |
|
|
2021
Q3 | $91.2M | Buy |
502,848
+54,804
| +12% | +$10.7M | 0.03% | 568 |
|
|
2021
Q2 | $90.3M | Buy |
448,044
+9,852
| +2% | +$2.06M | 0.03% | 557 |
|
|
2021
Q1 | $94.2M | Buy |
438,192
+79,543
| +22% | +$17.5M | 0.03% | 540 |
|
|
2020
Q4 | $84.8M | Buy |
358,649
+151,378
| +73% | +$34.7M | 0.03% | 542 |
|
|
2020
Q3 | $56.4M | Sell |
207,271
-59,517
| -22% | -$16.4M | 0.02% | 604 |
|
|
2020
Q2 | $77.5M | Sell |
266,788
-102,485
| -28% | -$27.8M | 0.03% | 443 |
|
|
2020
Q1 | $87.9M | Buy |
369,273
+68,650
| +23% | +$15.7M | 0.04% | 387 |
|
|
2019
Q4 | $65.8M | Sell |
300,623
-27,111
| -8% | -$5.49M | 0.02% | 618 |
|
|
2019
Q3 | $55.5M | Buy |
327,734
+75,783
| +30% | +$13.4M | 0.02% | 636 |
|
|
2019
Q2 | $46.2M | Buy |
251,951
+1,657
| +0.7% | +$290K | 0.02% | 705 |
|
|
2019
Q1 | $46M | Sell |
250,294
-23,776
| -9% | -$4.39M | 0.02% | 679 |
|
|
2018
Q4 | $45.4M | Sell |
274,070
-98,400
| -26% | -$17M | 0.02% | 633 |
|
|
2018
Q3 | $71.8M | Buy |
372,470
+17,670
| +5% | +$3.15M | 0.03% | 521 |
|
|
2018
Q2 | $60.3M | Sell |
354,800
-14,660
| -4% | -$2.27M | 0.03% | 563 |
|
|
2018
Q1 | $60.2M | Buy |
369,460
+55,878
| +18% | +$9.13M | 0.03% | 554 |
|
|
2017
Q4 | $47M | Buy |
313,582
+68,501
| +28% | +$10.1M | 0.02% | 705 |
|
|
2017
Q3 | $37.3M | Buy |
245,081
+500
| +0.2% | +$75.3K | 0.02% | 751 |
|
|
2017
Q2 | $31.5M | Buy |
244,581
+81,580
| +50% | +$9.82M | 0.02% | 791 |
|
|
2017
Q1 | $17.8M | Sell |
163,001
-82,528
| -34% | -$7.27M | 0.01% | 1102 |
|
|
2016
Q4 | $18.1M | Buy |
245,529
+14,173
| +6% | +$1.15M | 0.01% | 1087 |
|
|
2016
Q3 | $20.2M | Buy |
231,356
+45,262
| +24% | +$4.28M | 0.01% | 978 |
|
|
2016
Q2 | $16M | Sell |
186,094
-24,935
| -12% | -$2.15M | 0.01% | 1078 |
|
|
2016
Q1 | $16.8M | Sell |
211,029
-84,862
| -29% | -$7.68M | 0.01% | 995 |
|
|
2015
Q4 | $37.2M | Buy |
295,891
+62,634
| +27% | +$7.56M | 0.02% | 622 |
|
|
2015
Q3 | $24.3M | Sell |
233,257
-32,010
| -12% | -$4.11M | 0.02% | 775 |
|
|
2015
Q2 | $32.8M | Sell |
265,267
-21,605
| -8% | -$2.72M | 0.02% | 710 |
|
|
2015
Q1 | $33.8M | Sell |
286,872
-41,744
| -13% | -$5M | 0.02% | 669 |
|
|
2014
Q4 | $39M | Buy |
+328,616
| New | +$37M | 0.03% | 646 |
|
Other funds holding VRTX
VCM
VPM
UBS Group's VRTX Position: Q1 2026 in Review
UBS Group increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, buying an estimated $34.8M and bringing the position to 630,618 shares worth $282M. The position accounts for 0.04% of the portfolio, ranked #455.
UBS Group first reported a position in VRTX in Q4 2014 and has held it in 46 quarters since. The position peaked at $360M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- UBS Group held 630,618 shares of Vertex Pharmaceuticals worth $282M as of Q1 2026.
- UBS Group bought 74,636 Vertex Pharmaceuticals shares in Q1 2026, an estimated $34.8M.
- Vertex Pharmaceuticals made up 0.04% of UBS Group's portfolio in Q1 2026, its #455 holding.
- UBS Group first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Vertex Pharmaceuticals position peaked at $360M in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.